ConductScience.org, home

Trial · NCT07448506

Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension

NCT07448506, Phase 3, Completed, Laboratorios Richmond S.A.C.I.F.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension. Trials, record NCT07448506. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07448506

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
NCT number
NCT07448506
Status
Completed
Phases
Phase 3
Enrollment
50 participants, actual
Lead sponsor
Laboratorios Richmond S.A.C.I.F.
Conditions
High Blood Pressure (& [Essential Hypertension])
Interventions
Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
First posted
2026-03-04
Last updated
2026-08-13

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryMain Outcome8 week follow up
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult patients diagnosed with mild or moderate hypertension at week 8 of follow-up.
SecondaryProportion of Patients With Controlled Blood Pressure at Week 44 week follow up
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult patients diagnosed with mild or moderate hypertension at week 4 of follow-up.
SecondaryIncidence of Adverse Events4 week follow upTo evaluate the safety of Nifedipine 30mg Extended-Release Richmond versus an active comparator, measured by the proportion of adverse events identified during follow-up.
SecondaryIncidence of Serious Adverse Events8 week follow upTo evaluate the safety of Nifedipine 30mg Extended Release Richmond versus an active comparator, measured by the proportion of serious adverse events identified during follow-up.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07448506

GET https://conductscience.org/api/trials/v1/NCT07448506/registered